U.S. Breast Cancer Screening & Diagnostic Market Analysis and Forecast 2024-2030 - Multi-Modality Imaging Revolutionizes Breast Cancer Diagnostics, Boosting Detection Accuracy
16 janv. 2025 04h04 HE
|
Research and Markets
Dublin, Jan. 16, 2025 (GLOBE NEWSWIRE) -- The "U.S. Breast Cancer Screening and Diagnostic Market: Analysis and Forecast, 2024-2030" report has been added to ResearchAndMarkets.com's offering.The...
Breast Cancer Brachytherapy Market Sees $1.88 Billion Opportunity by 2035: Elekta, Varian Medical Systems, and Isoray Dominate the Competitive Landscape
13 janv. 2025 06h47 HE
|
Research and Markets
Dublin, Jan. 13, 2025 (GLOBE NEWSWIRE) -- The "Breast Cancer Brachytherapy Market by Technology, Product, End User, and Region" report has been added to ResearchAndMarkets.com's offering. This...
Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update
10 janv. 2025 07h00 HE
|
Arvinas Inc.
– Vepdegestrant to be combined with Pfizer’s novel investigational CDK4 inhibitor atirmociclib in a first-line Phase 3 trial planned to initiate in 2025; a second-line Phase 3 combination trial will...
Myriad Genetics Signs Agreement with Nationally Renowned Sports Broadcaster Hannah Storm to Promote the Importance of Knowing Family Cancer History
09 janv. 2025 16h30 HE
|
Myriad Genetics, Inc.
Myriad Genetics announced it signed an agreement with sports broadcaster Hannah Storm to promote the importance of knowing family cancer history.
AI-Supported Mammography Revolutionizes Breast Cancer Detection: Landmark German Study Proves Real-World Impact
07 janv. 2025 05h00 HE
|
Vara
Vara's PRAIM study shows AI boosts breast cancer detection by 17.6% in German screening of 500,000 participants; cutting radiologist workloads by 43%
Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook
26 déc. 2024 09h00 HE
|
FN Media Group LLC
PALM BEACH, Fla., Dec. 26, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The breast cancer drugs market is experiencing rapid expansion due to the diverse applications of drugs in...
Myriad Genetics’ RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics
19 déc. 2024 16h15 HE
|
Myriad Genetics, Inc.
Myriad Genetics announced a MyRisk® Hereditary Cancer Test with RiskScore® study was named as one of the top 10 significant advances in genomic medicine.
Medicenna Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium (SABCS)
13 déc. 2024 08h30 HE
|
Medicenna Therapeutics Corp.
Single-agent MDNA11 was more effective than a combination of immune checkpoint inhibitors (anti-mPD1 and anti-mCTLA4) in preventing metastasis and achieving long-term survival in an aggressive mouse...
Precede Biosciences Presents a Novel ER Transcriptional Dependency Index at SABCS 2024 Designed to Further Inform Use of Endocrine Therapy from a Simple Blood Test
12 déc. 2024 08h00 HE
|
Precede Biosciences, Inc.
Precede Bio’s ER dependency index (PERDI) tests for both ER dependent and ER independent mechanisms of cancer growth, addressing an important unmet need in the field todayThere are approximately...
Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium
10 déc. 2024 09h05 HE
|
Arvinas Inc.
– Vepdegestrant in combination with abemaciclib demonstrated encouraging clinical activity (clinical benefit rate: 62.5%; overall response rate: 26.7%) in patients previously treated with a CDK4/6...